EcoDrugPlus

Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit

Ensembl ID : ENSOKIG00005048485
Gene Symbol: EZH2
3 Cross references
235 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSOKIG00005029908
Gene Symbol: LOC109874573
3 Cross references
206 Possible Orthologues:

Epidermal Growth Factor Receptor-Like

Ensembl ID : ENSOKIG00005024025
Gene Symbol: LOC109871972
3 Cross references
206 Possible Orthologues:

Equilibrative Nucleoside Transporter 1

Ensembl ID : ENSOKIG00005022427
Gene Symbol: LOC109899784
3 Cross references
203 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSOKIG00005020149
Gene Symbol: LOC109890034
3 Cross references
203 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSOKIG00005021858
Gene Symbol: ERBB2
3 Cross references
200 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSOKIG00005003569
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSOKIG00005007688
Gene Symbol: ERBB3
3 Cross references
205 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSOKIG00005016708
Gene Symbol: ERBB4
1 Cross references
8 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSOKIG00005019215
Gene Symbol: ERBB4
1 Cross references
9 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 4

Ensembl ID : ENSOKIG00005040009
Gene Symbol: ERBB4
1 Cross references
229 Possible Orthologues:

Estrogen Receptor

Ensembl ID : ENSOKIG00005013214
Gene Symbol: LOC109866292
3 Cross references
207 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).